文献速递腹部CT

胃癌瘤周CT影像组学预测CLDN18.2表达的研究解读

Peritumoral CT radiomics reveals CLDN18.2-related imaging phenotypes beyond the tumor boundary in gastric cancer.
PubMed 文献 · Eur J Radiol · 2026-09-18

本研究为单中心回顾性研究,纳入210例病理确诊胃腺癌患者,基于治疗前增强CT静脉期图像提取瘤内及瘤周影像组学特征。结果显示瘤周模型预测CLDN18.2阳性的AUC在训练集为0.761、验证集为0.784,联合CA19-9与Borrmann分型的临床-影像组学列线图AUC达0.818和0.820。

要点

  • 瘤周区域影像组学特征对CLDN18.2阳性的判别效能数值上高于瘤内模型,阅片时应关注瘤周浸润带。
  • 联合CA19-9、Borrmann分型与瘤周RadScore的列线图可个体化预测CLDN18.2表达状态。
  • 瘤周纹理及强度分布特征对预测贡献较大,提示肿瘤-宿主交界区的微观结构改变有影像学对应。

核心结论

  • 瘤周CT影像组学能够捕获肿瘤可见边界之外的CLDN18.2相关影像表型,且判别效能数值上高于传统瘤内影像组学模型。
  • 瘤周区域可能为CLDN18.2相关的上皮重塑与肿瘤-宿主相互作用提供影像学观察窗口。

研究设计与样本

  • 所有患者均有治疗前增强CT及CLDN18.2免疫组化结果,CLDN18.2阳性106例、阴性104例,按151例训练集与59例验证集分组。
  • 图像分析采用5mm轴位静脉期重建图像,重采样至1×1×1 mm³各向同性体素后行全容积3D瘤内及瘤周ROI逐层勾画。
  • 影像组学特征经PyRadiomics提取,依次经方差过滤、Spearman冗余过滤及LASSO逻辑回归筛选,并整合独立预测因子构建列线图。

关键影像表现/征象

  • LASSO筛选最终保留4个瘤内影像组学特征和7个瘤周影像组学特征用于模型构建。
  • SHAP分析显示瘤周纹理特征与强度分布特征对模型预测有重要贡献。

诊断标准与关键数值

  • 瘤周模型预测CLDN18.2阳性的AUC为训练集0.761、验证集0.784;瘤内模型对应AUC为0.756和0.761。
  • 多因素分析中瘤周RadScore与CLDN18.2阳性独立相关,OR为3.23,95%CI为2.08-5.02,P<0.001。
  • 联合CA19-9、Borrmann分型与瘤周RadScore的临床-影像组学列线图AUC为训练集0.818、验证集0.820。

临床应用与阅片要点

  • 日常阅片时除观察肿块本身外,应关注瘤周浸润带的形态与密度不均质性,可能反映CLDN18.2相关生物学特征。
  • 对于拟行CLDN18.2靶向治疗筛选的胃癌患者,列线图可提供个体化表达概率预估的影像学参考。

局限性

  • 单中心回顾性研究设计本身存在选择偏倚与外部泛化能力受限的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: CLDN18.2 is an actionable biomarker in gastric cancer and a tight-junction protein implicated in epithelial adhesion and barrier integrity. Alterations in CLDN18.2-related junctional biology may influence tumor invasion, epithelial remodeling, and tumor-host interaction at the invasive front. We hypothesized that CLDN18.2-associated biological alterations extend beyond the tumor boundary and may therefore be captured more effectively by peritumoral CT radiomics than by conventional intratumoral radiomics.

METHODS: This single-center retrospective study included 210 patients with pathologically confirmed gastric adenocarcinoma and available pre-treatment contrast-enhanced CT and CLDN18.2 immunohistochemistry results between January 2023 and December 2025. Patients were divided into a training cohort (n = 151) and a validation cohort (n = 59). CLDN18.2 expression was determined by immunohistochemistry using surgical resection or biopsy specimens as clinically available. For image analysis, 5-mm axial venous-phase reconstructed images were resampled to 1 × 1 × 1 mm3 isotropic voxels before slice-by-slice whole-volume 3D intratumoral and peritumoral ROI segmentation. Radiomics features were extracted using PyRadiomics, followed by variance filtering, Spearman redundancy filtering, and LASSO logistic regression. Intratumoral and peritumoral radiomics models were evaluated, and independent predictors were integrated into a clinicoradiomic nomogram as a clinical translation of the peritumoral imaging signature. Model assessment included ROC analysis, calibration analysis, decision curve analysis, and SHAP interpretation.

RESULTS: Among 210 patients, 106 were CLDN18.2-positive and 104 were CLDN18.2-negative. LASSO selection retained 4 intratumoral and 7 peritumoral radiomics features. The peritumoral model yielded AUCs of 0.761 in the training cohort and 0.784 in the validation cohort, compared with 0.756 and 0.761 for the intratumoral model, respectively. Peritumoral RadScore remained independently associated with CLDN18.2 positivity in multivariable analysis (OR, 3.23; 95% CI, 2.08-5.02; P < 0.001). A clinicoradiomic nomogram incorporating CA19-9, Borrmann type, and Peritumoral RadScore achieved AUCs of 0.818 in the training cohort and 0.820 in the validation cohort, with acceptable calibration and potential clinical utility. SHAP analysis indicated that peritumoral texture and intensity-distribution features contributed substantially to model prediction.

CONCLUSIONS: Peritumoral CT radiomics captured CLDN18.2-associated imaging phenotypes beyond the visible tumor boundary and showed numerically higher discrimination than conventional intratumoral radiomics. These findings suggest that the peritumoral region may provide an imaging window into features consistent with CLDN18.2-associated epithelial remodeling and tumor-host interaction. The clinicoradiomic nomogram provides a potential clinical translation of this peritumoral imaging phenotype for individualized prediction of CLDN18.2 positivity.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Qi, Jiao, Wei, et al. Peritumoral CT radiomics reveals CLDN18.2-related imaging phenotypes beyond the tumor boundary in gastric cancer. Eur J Radiol. 2026. PMID: 42790057. doi:10.1016/j.ejrad.2026.113246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。